Separate terms with OR to return results that match either term.
 
Clear All

9,394 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
47426-0201-01 47426-0201 aprepitant CINVANTI 130.0 mg/18mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 3, 2018 In Use
43066-0001-01 43066-0001 docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 19, 2018 In Use
43066-0006-01 43066-0006 docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 19, 2018 In Use
43066-0010-01 43066-0010 docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 19, 2018 In Use
43598-0682-35 43598-0682 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 13, 2018 In Use
43598-0683-25 43598-0683 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 13, 2018 In Use
68001-0345-36 68001-0345 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 16, 2018 In Use
68001-0345-26 68001-0345 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 16, 2018 In Use
69488-0003-01 69488-0003 Lutetium Lu 177 dotatate Lutathera 10.0 mCi/mL Chemotherapy Radiopharmaceutical Somatostatin Analog Intravenous Jan. 26, 2018 In Use
55700-0627-10 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Oral May 18, 2018 In Use
55700-0627-12 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Oral May 18, 2018 In Use
55700-0627-20 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Oral May 18, 2018 In Use
55700-0627-30 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Oral May 18, 2018 In Use
55700-0631-06 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Oral May 25, 2018 In Use
55700-0631-10 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Oral May 25, 2018 In Use
55700-0631-20 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Oral May 25, 2018 In Use
55700-0631-30 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Oral May 25, 2018 In Use
16714-0815-01 16714-0815 zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Intravenous May 30, 2018 In Use
54288-0100-01 54288-0100 ZOLEDRONIC ACID ZOLEDRONIC ACID 4.0 mg/5mL Ancillary Therapy Intravenous April 2, 2018 In Use
00527-1452-06 00527-1452 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Oral May 18, 2018 In Use
00527-1451-06 00527-1451 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Oral May 18, 2018 In Use
00527-1450-06 00527-1450 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Oral May 18, 2018 In Use
69639-0102-01 69639-0102 Fosnetupitant and Palonosetron AKYNZEO 260.0 mg/1, 0.28 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Intravenous April 20, 2018 In Use
68001-0359-37 68001-0359 GEMCITABINE GEMCITABINE 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 25, 2018 In Use
68001-0350-68 68001-0350 GEMCITABINE GEMCITABINE 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 25, 2018 In Use
68001-0348-36 68001-0348 GEMCITABINE GEMCITABINE 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 25, 2018 In Use
68001-0342-34 68001-0342 GEMCITABINE GEMCITABINE 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 25, 2018 In Use
47335-0401-81 47335-0401 abiraterone acetate YONSA 125.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 22, 2018 In Use
43598-0650-11 43598-0650 Thiotepa Thiotepa 15.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical May 4, 2018 In Use
59651-0205-08 59651-0205 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 17, 2018 In Use
59651-0205-10 59651-0205 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 17, 2018 In Use
59651-0204-10 59651-0204 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 17, 2018 In Use
59651-0204-60 59651-0204 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 17, 2018 In Use
70121-1240-01 70121-1240 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral May 31, 2018 In Use
70121-1239-01 70121-1239 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral May 31, 2018 In Use
70121-1238-01 70121-1238 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral May 31, 2018 In Use
69097-0316-02 69097-0316 exemestane EXEMESTANE 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral April 27, 2018 In Use
16729-0332-03 16729-0332 OXALIPLATIN OXALIPLATIN 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 17, 2018 In Use
16729-0332-05 16729-0332 OXALIPLATIN OXALIPLATIN 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 17, 2018 In Use
00078-0958-19 00078-0958 tisagenlecleucel KYMRIAH 60000000.0 1/1 Immunotherapy CAR-T CD19 Intravenous May 1, 2018 In Use
25021-0828-50 25021-0828 leucovorin calcium Leucovorin Calcium 500.0 mg/50mL Ancillary Therapy Intramuscular, Intravenous April 15, 2018 In Use
16714-0816-01 16714-0816 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral June 1, 2018 In Use
16714-0816-02 16714-0816 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral June 1, 2018 In Use
71837-5843-05 71837-5843 SARGRAMOSTIM Leukine 250.0 ug/mL Ancillary Therapy Intravenous, Subcutaneous May 30, 2018 In Use
00409-0323-20 00409-0323 BLEOMYCIN Bleomycin 30.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous April 25, 2018 In Use
00781-3312-75 00781-3312 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 23, 2018 In Use
00703-4094-01 00703-4094 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 23, 2018 In Use
25021-0783-05 25021-0783 palonosetron hydrochloride palonosetron hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 15, 2018 In Use
16714-0834-01 16714-0834 Palonosetron Palonosetron 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 29, 2018 In Use
68001-0355-25 68001-0355 Palonosetron Palonosetron 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 30, 2018 In Use

Found 9,394 results in 7 millisecondsExport these results